By Ethan Covey
RBX2660, a novel microbiota-based live biotherapeutic, consistently reduced recurrent Clostridioides difficile infection (rCDI) among patients who are 65 years of age and older, according to data presented at IDWeek 2022, held in Washington, D.C. (poster 236).
RBX2660, which was developed by Rebiotix, a Ferring Pharmaceuticals company, is being studied for its potential to reduce recurrence of CDI following antibiotic treatment.
“Advanced age and certain underlying